CCR7 ligand delivery and co-delivery in immunotherapy

• US 8,592,364 B2
• Filed: 02/10/2011
• Issued: 11/26/2013
• Est. Priority Date: 02/11/2010
• Status: Active Grant

• Current Assignee: Ecole polytechnique fãdãrale de lausanne epfl (Schweizerische Eidgenossenschaft)
• Original Assignee: Ecole polytechnique fãdãrale de lausanne epfl (Schweizerische Eidgenossenschaft)
• Inventors: Swartz, Melody A., Hubbell, Jeffrey A., Tomei, Alice A., Shields, Jacqueline D., Kourtis, Iraklis
• Primary Examiner(s): KEMMERER, ELIZABETH
• Application Number:
  US13/025,009
• Publication Number:
  US 20110206759A1
• Time in Patent Office: 1,020 Days
• Field of Search: None
• US Class Current: 514/1.1
• CPC Class Codes: A61K 2039/55522 Cytokines; Lymphokines; Interferons
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 38/1841 Transforming growth factor [TGF]
• CPC Class Codes: A61K 38/195 Chemokines, e.g. RANTES
• CPC Class Codes: A61K 38/20 Interleukins [IL]
• CPC Class Codes: A61K 38/2066 IL-10
• CPC Class Codes: A61K 39/001 Preparations to induce tolerance to non-self, e.g. prior to transplantation
• CPC Class Codes: A61L 2300/252 Polypeptides, proteins, e.g. glycoproteins, lipoproteins, cytokines
• CPC Class Codes: A61L 2300/414 Growth factors
• CPC Class Codes: A61L 2300/62 Encapsulated active agents, e.g. emulsified droplets
• CPC Class Codes: A61L 27/54 Biologically active materials, e.g. therapeutic substances A61L27/227 takes precedence
• CPC Class Codes: A61L 27/60 Materials for use in artificial skin
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 37/00 Drugs for immunological or allergic disorders
• CPC Class Codes: A61P 37/06 Immunosuppressants, e.g. drugs for graft rejection
• CPC Class Codes: C12N 15/86 Viral vectors
• CPC Class Codes: C12N 2740/15043 viral genome or elements thereof as genetic vector
• CPC Class Codes: C12N 2740/15052 relating to complementing cells and packaging systems for producing virus or viral particles

Abstract

Chemokines may be administered to a patient for immunotolerization. Chemokines include CCL19 and CCL21. Materials and methods for accomplishing tolerization and described.

Claims

1. A method of treating a human patient receiving a tissue implant to achieve immunotolerance to the implant, the implant having exogenous antigens, the method comprising:

administering a chemokine to the human patient to establish adaptive immune system treatment of the exogenous antigens as self-antigens to thereby achieve immunotolerance to the implant, the chemokine being chosen from the group consisting of CC-chemokine ligand-19 (CCL19), CC-chemokine ligand-21 (CCL21), and combinations thereof.

2. The method of claim 1 wherein the administration is made locally at the implant.

3. The method of claim 2 wherein the chemokine is delivered transdermally or in a microparticle, liposome, or micelle.

4. The method of claim 2 further comprising establishing a concentration gradient of the chemokine that is maximal at the tissue implant.

5. The method of claim 4 wherein an implantable pump releases the chemokine.

6. The method of claim 2 further comprising releasing the chemokine from a matrix implanted in the patient.

7. The method of claim 6 wherein the matrix comprises fibrin.

8. The method of claim 7 wherein the tissue implant comprises a skin graft placed over the fibrin.

9. The method of claim 6 wherein the matrix comprises a covalently crosslinked biodegradable hydrogel.

10. The method of claim 1 further comprising administering an upregulator of T-cells.

11. The method of claim 10 wherein the upregulator comprises a member of the group consisting of Transforming Growth Factor beta (TGF-β

), Interleukin-10 (IL-10), Interleukin-35 (IL-35), and combinations thereof.

12. The method of claim 10 wherein the upregulator is administered locally and the chemokine is administered systematically.

13. The method of claim 1 wherein the chemokine is a portion of a fusion protein.

14. The method of claim 13 comprising the administration of a plurality of fusion proteins that are different from each other, with the proteins each comprising at least one member of the group consisting of CCL19 and CCL21.

15. The method of claim 1 further comprising a second implantation of more of the same tissue, with the second implantation being made without administration of the chemokine.

16. The method of claim 1 wherein administration of the chemokine comprises release of the chemokine from an implanted cell genetically modified to overexpress the chemokine.

17. The method of claim 1 wherein the tissue is chosen from the group consisting of stem cells, islets of Langerhans, stem cell-derived pancreatic beta cell-like cells, cardiomyocytes, stem cell-derived cardiomyocyte precursors to restore cardiac function, endothelial cells, and endothelial progenitor cells.

18. The method of claim 1 further comprising encapsulating the tissue.

19. The method of claim 1 wherein the encapsulating material substantially limits contact of the tissue with immune cells in the patient and allows at least some of the immune cells to contact the tissue.

20. The method of claim 13, wherein the fusion protein comprises a protein chosen from the group consisting of a transglutaminase substrate, a heparin-binding domain, a fibrin-binding domain, a protease substrate, Transforming Growth Factor beta (TGF-β

), Interleukin-10 (IL-10), and Interleukin-35 (IL-35).

21. The method of claim 13, wherein the fusion protein comprises a motif for binding to fibrin and a member of the group consisting of Transforming Growth Factor beta (TGF-β

), Interleukin-10 (IL-10), Interleukin-35 (IL-35).

22. The method of claim 13, wherein the fusion protein comprises a transglutaminase substrate and a plasmin substrate.

23. A method of inducing immunotolerization for a tissue implanted in a human patient, said tissue having exogenous antigens, the method comprising

administering a chemokine to the human patient in combination with the tissue, with the chemokine being administered in an amount effective to establish adaptive immune system treatment of the exogenous antigens as self-antigens to thereby achieve immunotolerization to the tissue chosen from the group consisting of CC-chemokine ligand-19 (CCL19), CC-chemokine ligand-21 (CCL21), and combinations thereof.

24. The method of claim 23 further comprising withdrawal of immunosuppressant treatment after tolerization is achieved.

25. The method of claim 23 wherein the chemokine is administered over a period of time and then no longer administered to the patient, the time being in a range between one month and twelve months.

26. The method of claim 23 further comprising administering, in combination with the chemokine, an upregulator of T-cells, wherein the upregulator is chosen from the group consisting of TGF- β

, IL-10, and IL-35.